Clinical trial · Observational
Prospective, Observational Study of Biomarkers in Liver Cancer - Identification of Actionable Events
NCT01963949CI-TRIAL-00014568withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To collect tumor tissue from patients with liver masses suspicious for primary liver cancer. The research biopsy will be used to identify biomarkers in future studies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Primary Liver Cancer
- description
- Patients that have liver masses suspicious for primary liver cancer.
Primary outcomes (1)
- measure
- Biopsy of Liver Masses
- timeFrame
- 5 years
- description
- To obtain tissue from biopsy of liver masses suspicious for primary liver cancer for use in future biomarker studies.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: 1. Liver mass suspicious for primary liver cancer with a diagnostic liver biopsy planned as a part of clinical care 2. Age ≥ 18 years. 3. ECOG performance status 0-2 4. Adequate organ and marrow function as defined below: INR ≤ 1.5 platelets ≥ 70,000/mcl 5. Ability to understand and the willingness to sign a written informed consent 6. Target liver mass not subcapsular in nature as determined by the participating biopsy team 7. Child Pugh Turcotte score A or B Exclusion Criteria: 1. Previous treatment for HCC 2. Any contraindication for clinical-care liver biopsy, including anti-coagulation therapy that cannot be discontinued prior to biopsy or large volume ascites
References
Publications (0)
Data not yet available
No reference posted for this study.